Compare iShares Core High Dividend ETF (HDV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Core High Dividend ETF trades at $29.71 (market cap $15.11B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Core High Dividend ETF is far larger — about 2× Spyre Therapeutics Inc. Common Stock's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 118 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HDV | SYRE | |
|---|---|---|
Market Cap | $15.11B | $7.52B |
Volume | 2,559,662 | 1,441,031 |
52-Week High | $29.93 | $108.92 |
52-Week Low | $23.64 | $22.18 |
Typical Hold Time | 118 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.15, up 0.28% with a bullish technical signal from moving averages. The ETF recently underwent a significant sector rebalance, reducing healthcare exposure while increasing energy, staples, and utilities. Technical indicators show strong momentum with RSI at 66.71 suggesting neutral conditions, while ADX readings indicate a strong trend. Recent dividend distributions of $0.10 and $0.06 demonstrate the fund's income-focused strategy.
The ETF's concentrated sector allocation (62% in three sectors) presents both opportunity and risk. While the 3% yield attracts income investors, the reduced diversification may increase vulnerability to sector-specific headwinds. Technical strength supports near-term upside, but investors should weigh the trade-off between current income and long-term growth potential given the sector concentration.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
